Tien Luk - CytoMed Therapeutics Chief Director
| GDTC Stock | 2.96 0.47 13.70% |
Director
Tien Luk is Chief Director of CytoMed Therapeutics Limited
| Age | 38 |
| Address | 1 Commonwealth Lane, No. 08-22, Singapore, Singapore, 149544 |
| Phone | 65 6250 7738 |
| Web | https://w2.cytomed.sg |
CytoMed Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1744) % which means that it has lost $0.1744 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2626) %, meaning that it created substantial loss on money invested by shareholders. CytoMed Therapeutics' management efficiency ratios could be used to measure how well CytoMed Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of January 7, 2025, Return On Tangible Assets is expected to decline to -0.31. In addition to that, Return On Capital Employed is expected to decline to -0.3. At present, CytoMed Therapeutics' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 12.2 M, whereas Net Tangible Assets are forecasted to decline to about 485.8 K.Similar Executives
| Found 2 records | DIRECTOR Age | ||
| Patrick Lin | Processa Pharmaceuticals | 60 | |
| Susan Berland | Senti Biosciences | 69 | |
Management Performance
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.17 |
CytoMed Therapeutics Leadership Team
Elected by the shareholders, the CytoMed Therapeutics' board of directors comprises two types of representatives: CytoMed Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CytoMed. The board's role is to monitor CytoMed Therapeutics' management team and ensure that shareholders' interests are well served. CytoMed Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CytoMed Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yoong Tan, Chief Officer | ||
| Tien MD, Chief Officer | ||
| Jieming Zeng, Chief Director | ||
| Yvonne Goh, Chief Officer | ||
| Chee Choo, Executive Chairman | ||
| Tien Luk, Chief Director | ||
| Jieming MD, Chief Director | ||
| Wee Tan, COO Director |
CytoMed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CytoMed Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.17 | ||||
| Operating Margin | (7.36) % | ||||
| Current Valuation | 35.17 M | ||||
| Shares Outstanding | 11.54 M | ||||
| Shares Owned By Insiders | 69.27 % | ||||
| Shares Owned By Institutions | 0.04 % | ||||
| Number Of Shares Shorted | 62.69 K | ||||
| Price To Book | 5.34 X | ||||
| Price To Sales | 88.41 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in CytoMed Therapeutics Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytoMed Therapeutics. If investors know CytoMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytoMed Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.22) | Revenue Per Share | Quarterly Revenue Growth (0.21) | Return On Assets | Return On Equity |
The market value of CytoMed Therapeutics is measured differently than its book value, which is the value of CytoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CytoMed Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytoMed Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytoMed Therapeutics' market value can be influenced by many factors that don't directly affect CytoMed Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytoMed Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytoMed Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytoMed Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.